Quote | Satellos Bioscience Inc. (TSXVC:MSCL:CC)
Last: | $0.93 |
---|---|
Change Percent: | -2.11% |
Open: | $0.93 |
Close: | $0.93 |
High: | $0.96 |
Low: | $0.89 |
Volume: | 50,284 |
Last Trade Date Time: | 05/06/2022 04:56:05 pm |
News | Satellos Bioscience Inc. (TSXVC:MSCL:CC)
Satellos Bioscience Inc. Opens the Market Canada NewsWire TORONTO , May 15, 2024 /CNW/ - Frank Gleeson Co-Founder and Chief Executive Officer, Satellos Bioscience Inc. (TSX: MSCL) ("Satellos" or the "Company"), and his team joined Dani Lipkin , Managing Direc...
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“ Satellos ” or the “ Company ”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today the results of...
Message Board Posts | Satellos Bioscience Inc. (TSXVC:MSCL:CC)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Satellos Bioscience Inc. Company Name:
MSCL:CC Stock Symbol:
TSXVC Market:
Satellos Bioscience Inc. Opens the Market Canada NewsWire TORONTO , May 15, 2024 /CNW/ - Frank Gleeson Co-Founder and Chief Executive Officer, Satellos Bioscience Inc. (TSX: MSCL) ("Satellos" or the "Company"), and his team joined Dani Lipkin , Managing Direc...
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“ Satellos ” or the “ Company ”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today the results of...
- Conducted preclinical toxicology studies and GMP manufacturing of SAT-3247 - On track to initiate Phase 1 first-in-human clinical trials mid-2024 - Cash balance of $33.2 million at March 31, 2024 - Invited to present at PPMD 30 th annual conference to be held J...